Kang DY, et al. - In this randomized, multicenter, prospective trial, Resolute zotarolimus-eluting stents (R-ZES) and Xience everolimus-eluting stents (EES) were compared for efficacy in very long (≥50 mm) coronary lesions. Comparable baseline characteristics were seen in the R-ZES and EES groups, with 49.6±10.2 and 50.6±13.3 mm lesion length, respectively, and the number of stents used at the target lesion was 2.1±0.3 and 2.2±0.5, respectively. Including 50% of eligible patients, 12-month angiographic follow-up was carried out, which revealed similar angiographic and clinical outcomes of R-ZES vs EES implantation in patients with very long native coronary artery disease. The R-ZES and EES groups showed no significant difference in in-segment late luminal loss (0.17±0.57 vs 0.09±0.43 mm). In the R-ZES and EES groups, rates of in-segment binary restenosis were 8.1% and 5.3%, respectively. With regard to the rate of adverse events (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes), no significant between-group differences were observed.